Contact us
Young GI
Patients
Industry
Press
My Connect
Create myUEG account
About
To landing page
Who we are
Boards, Committees & Groups
Governance
Headquarters Management
History
What we do
Strategic Drivers
Year in Review
Our Members
Specialist Member Societies
National Member Societies
myUEG Community
myUEG Associates
My Connect
Women in GI
Young GIs
Researchers
Event Calendar
Week
To landing page
Attendance
Registration fees
Hotel
Venue
Eco-friendly info
Programme
Abstract Submission
Postgraduate Teaching
Nurse Programme
Hands-on
Industry Programme
Acknowledgements
CME Accreditation
UEG Week on-demand
Congress Resources
Education
To landing page
Online Education
Online Courses
Webinars
Career Development
Face-to-face Education
Summer School
Masterclass
Clinical Visiting Fellowships
Education Resources
Mistakes in...
UEG Talks Podcast
Image Hub
CME in Europe
Event Endorsement
Supporters
Research
To landing page
Support
Horizon Europe Support
Projects
Research Prize
Research Fellowship
Research Webinars
Advocacy
Position Papers
White Book 2
Main Results
Full Reports
Materials and Presentations
Quality of Care
To landing page
Search Guidelines
Standards & Guidelines Repository
Non-English Guidelines
GI Guidelines App
Develop & Implement
Guideline development framework
Guideline development course
Get Funding
Get Endorsement
Guideline Webinars
Projects
Quality of Care Initiatives
Quality Standards
Public Affairs
To landing page
Advocacy
Core Positions
Stakeholder Collaboration
White Book 2
Position Papers
MEP Digestive Health Group
Our Supporters
#EUNewsline →
EU Elections 2024
Publications
To landing page
Publications
Congress Publications
Research Publications
Public Affairs Publications
Education Publications
UEG Publications
UEG Journal →
UEG Journal Podcast
White Book 2
Opportunities
To landing page
Congress Opportunities
Top Abstract Prizes
National Scholar Award
Travel Grants
International Scholarship Awards
Research Funding
Research Prize
Research Fellowship
Horizon Europe Application Support
Activities Funding
Recognition of Achievements
Lifetime Achievement Award
Journal Best Paper Award
Activities Endorsement
Professional Advancement
Rising Star Awards
Clinical Visiting Fellowships
Open Positions
Talent Pool
Library
To landing page
Congress Resources
UEG Week on-demand
Abstracts
Posters
Guideline Resources
Education Resources
Image Hub
Webinars
Mistakes in... articles
Contact us
Young GI
Patients
Industry
Press
Author
Silvio Danese
SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE: POST HOC ANALYSIS OF LIBERTY-UC STUDY AND LIBERTY-CD STUDY
Silvio Danese
et al.
Evolving treatment goals and unmet needs in ulcerative colitis: how to address the gaps? (Takeda Pharmaceuticals International AG)
Silvio Danese
et al.
SYMPTOMS AND LABORATORY VALUES AS PROXIES FOR ENDOSCOPIC AND HISTOLOGIC CLINICAL ENDPOINTS IN ULCERATIVE COLITIS: A MEDIATION ANALYSIS BASED ON UPADACITINIB PHASE 3 INDUCTION TRIALS
Weighing up treatment options in UC: how do we interpret the evidence for JAK inhibition? (Pfizer)
Silvio Danese
et al.
DURABILITY OF SYMPTOMATIC AND CLINICAL OUTCOMES IN OZANIMOD-TREATED PATIENTS BY ENDPOINTS OF INCREASING OBJECTIVITY AT TRUE NORTH WEEK 52: INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
Silvio Danese
et al.
EFFECT OF ETRASIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
Silvio Danese
et al.
PRA023, AN ANTI-TL1A INHIBITORY ANTIBODY, REDUCED INFLAMMATORY AND FIBROSIS ASSOCIATED BIOMARKERS IN ULCERATIVE COLITIS PATIENTS WHO ACHIEVED CLINICAL REMISSION
Silvio Danese
et al.
WORLDWIDE POST-MARKETING SAFETY SURVEILLANCE EXPERIENCE WITH TOFACITINIB IN ULCERATIVE COLITIS
EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL
Silvio Danese
et al.
THE PHARMACOKINETICS AND IMMUNOGENICITY OF USTEKINUMAB AND ADALIMUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE SEAVUE STUDY
Silvio Danese
et al.
EFFECTS OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY ON DISEASE CLEARANCE IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS
LONG-TERM TREATMENT WITH SUBCUTANEOUS VEDOLIZUMAB IN CROHN’S DISEASE: INTERIM RESULTS FROM THE VISIBLE OPEN-LABEL EXTENSION STUDY
Silvio Danese
et al.
RAPIDITY OF SYMPTOM IMPROVEMENTS DURING FILGOTINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
LONG-TERM SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) AND RELAPSING MULTIPLE SCLEROSIS (RMS) STUDIES
EFFECTS OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY ON DISEASE CLEARANCE IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS
Silvio Danese
et al.
ACHIEVEMENT OF STRINGENT EFFICACY ENDPOINTS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE TREATED WITH UPADACITINIB
Silvio Danese
et al.
SAFETY OF USTEKINUMAB ACROSS APPROVED ADULT INDICATIONS: POOLED SAFETY ANALYSIS IN CROHN’S DISEASE, ULCERATIVE COLITIS, PSORIASIS, AND PSORIATIC ARTHRITIS THROUGH UP TO 5 YEARS
Small molecules for Crohn's disease
Silvio Danese
EFFECT OF ETRASIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY
Silvio Danese
et al.
Item 21 - 40 / 122
1
2
3
4
5
6
7
Chat with us
, powered by
LiveChat